Skip to main content
U.S. flag

An official website of the United States government

Biomarkers: Peripheral blood-based molecular signatures (Milestone 9.G)


Timeline Start - End

2016 - 2020

Research Implementation Area


Initiate studies to link peripheral blood-based molecular signatures and central imaging and CSF biomarkers.

Success Criteria

Identification of 3 peripheral blood-based molecular signatures that have a high correlation with central imaging and/or CSF biomarkers.

Summary of Key Accomplishments

Research supported by the NIA led to the discovery and ongoing standardization/validation of plasma amyloid, tau and neurofilament light chain (NfL) biomarkers, reflecting accumulation of amyloid and tau in the brain and neurodegeneration. NIA supports a growing portfolio of projects focused on using genomic technologies (transcriptomic, proteomic, metabolomic) to discover blood-based and CSF-based biomarkers that can be used for diagnostic, prognostic purposes or as biomarkers of treatment response. These include projects that are using single-cell molecular profiling technologies.

Studies supported through the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP AD) have identified multiple blood and CSF metabolite-based and protein-based signatures that correlate with CNS imaging biomarkers for AD for early and advanced stages of the disease.

The key accomplishments summary is current as of March 2022. 

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health